Next Article in Journal
The HTLV-1 Virological Synapse
Next Article in Special Issue
The “Connection” Between HIV Drug Resistance and RNase H
Previous Article in Journal
Innate Antiviral Immune Responses to Hepatitis B Virus
Previous Article in Special Issue
Resistance to Integrase Inhibitors
Viruses 2010, 2(7), 1411-1426; doi:10.3390/v2071411

Role of Gag in HIV Resistance to Protease Inhibitors

1,2,3,*  and 4,5
1 Inserm U941, Paris 75010, France 2 Institut Universitaire d’Hématologie, Université Paris Diderot, Paris 75010, France 3 Hôpital Saint Louis, AP-HP, Paris 75010, France 4 Institut Pasteur, Unité Virus et Immunité, Paris 75015, France 5 CNRS URA 3015, Paris 75015, France
* Author to whom correspondence should be addressed.
Received: 7 April 2010 / Revised: 21 June 2010 / Accepted: 25 June 2010 / Published: 5 July 2010
(This article belongs to the Special Issue HIV Drug Resistance 2010)
View Full-Text   |   Download PDF [671 KB, uploaded 12 May 2015]   |   Browse Figures


Cleavage of Gag and Gag-Pol precursors by the viral protease is an essential step in the replication cycle of HIV. Protease inhibitors, which compete with natural cleavage sites, strongly impair viral infectivity and have proven to be highly valuable in the treatment of HIV-infected subjects. However, as with all other antiretroviral drugs, the clinical benefit of protease inhibitors can be compromised by resistance. One key feature of HIV resistance to protease inhibitors is that the mutations that promote resistance are not only located in the protease itself, but also in some of its natural substrates. The best documented resistance-associated substrate mutations are located in, or near, the cleavage sites in the NC/SP2/p6 region of Gag. These mutations improve interactions between the substrate and the mutated enzyme and correspondingly increase cleavage. Initially described as compensatory mutations able to partially correct the loss of viral fitness that results from protease mutations, changes in Gag are now recognized as being directly involved in resistance. Besides NC/SP2/p6 mutations, polymorphisms in other regions of Gag have been found to exert various effects on viral fitness and or resistance, but their importance deserves further evaluation.
Keywords: HIV-1; protease; resistance; mutations; Gag HIV-1; protease; resistance; mutations; Gag
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Clavel, F.; Mammano, F. Role of Gag in HIV Resistance to Protease Inhibitors. Viruses 2010, 2, 1411-1426.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert